Global Stem Cell Partnering Deals Collection (2010-2020): Access to Headline, Upfront, Milestone and Royalty Data

News provided by

May 18, 2020, 08:15 ET

DUBLIN, May 18, 2020 /PRNewswire/ -- The "Global Stem Cell Partnering Terms and Agreements 2010-2020" report has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in Stem Cell dealmaking in the biopharma industry since 2010
Analysis of Stem Cell deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life Stem Cell deals
Access to Stem Cell contract documents
Leading Stem Cell deals by value since 2010
Most active Stem Cell dealmakers since 2010

The report provides a detailed understanding and analysis of how and why companies enter Stem Cell partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Stem Cell agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Stem Cell deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Stem Cell partnering deals.

The report presents financial deal term values for Stem Cell deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Stem Cell partnering field; both the leading deal values and most active Stem Cell dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 600 online deal records of actual Stem Cell deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Stem Cell dealmaking.

Chapter 1 provides an introduction to the report
Chapter 2 provides an overview of the trends in Stem Cell dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading Stem Cell deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in Stem Cell dealmaking with a brief summary followed by a comprehensive listing of Stem Cell deals announced by that company, as well as contract documents, where available.
Chapter 5 provides a comprehensive and detailed review of Stem Cell partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of Stem Cell partnering deals signed and announced since Jan 2010. The - Chapter is organized by specific Stem Cell technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Stem Cell partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Stem Cell partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Stem Cell technologies and products.

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Companies Mentioned

A*STAR Agency for Science
Technology and Research
A*STAR Genome Institute of Singapore
Accellta
Access BIO
Aelan Cell Technologies
AGC Asahi Glass
AiVita Biomedical
Akron Biotechnology
Allele Biotechnology and Pharmaceuticals
American CryoStem
American society of Hematology
Angiocrine Bioscience
Angionetics
Angiostem
Anthony Nolan
Apceth
Aratana Therapeutics
Ascendance Biotechnology
Astellas Pharma
Asterand Bioscience
Asterias Biotherapeutics
AstraZeneca
Athersys
Australian Research Council
Axcelead Drug Discovery Partners
Axiogenesis
AxoSim
Bassett Salon Solutions
Bayer USA Foundation
Baylor Research Institute
Beckman Research Institute of City of Hope
Berlin-Brandenburg Center for Regenerative Therapies
Be The Match BioTherapies
Beyond Type 1
Bio-Techne
BioBridge Global
BioCardia
BioHeart
Biological Industries
Biomed
BioRestorative Therapies
Biosafe
Biotech Products Services & Research
BlueRock Therapeutics
Boehringer Ingelheim
BrainStorm Cell Therapeutics
Brigham and Women's Hospital
Caladrius Biosciences
Calidi Biotherapeutics
California Institute for Regenerative Medicine
California State University
California Stem Cell
Calimmune
Canadian National Transplant Research Program
CareDx
Case Western Reserve University
CASI Pharmaceuticals
Catalent Pharma Solutions
Cedars-Sinai Medical Center
Celgene
Cell2in
Cell Applications
Cellaria Biosciences
Cell Care Therapeutics
Cellect Biotechnology
Cellectricon
Celling Biosciences
CellProThera
Celltex Therapeutics
Cell Therapy Catapult
Cellular Biomedicine
Cellular Dynamics International
Celularity
Censo Biotechnologies
Center for iPS Cells Research and Application
Centogene
Centre for Commercialization of Regenerative Medicine (CCRM)
Centre for Drug Research and Development (CDRD)
Cesca Therapeutics
Charite-Universitatsmedizin
Children's Hospital Boston
China Cord Blood
China Southeast University
Cincinnati Children's Hospital Medical Center
City of Hope
Clontech Laboratories
Cognate BioServices
and many, many more!

For more information about this report visit https://www.researchandmarkets.com/r/9pqrta

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets